Wells Fargo Maintains Overweight on Rhythm Pharmaceuticals, Raises Price Target to $144
Rhythm Pharmaceuticals, Inc.
Rhythm Pharmaceuticals, Inc. RYTM | 0.00 |
Wells Fargo analyst Derek Archila maintains Rhythm Pharmaceuticals (NASDAQ:
RYTM) with a Overweight and raises the price target from $143 to $144.